STOP T1D’s Post

https://lnkd.in/eQBb6rqz What does it take to deliver the needleless vascular access that people with kidney failure demand? Thanks to American Society of Nephrology Kidney News for writing up the recent Kidney Health Initiative workshop on patient and commercial requirements for vascular access innovations. So what does it take? Curious where people think ASN/KHI can have the most impact: 1. Real World Evidence/Registries/CRNs 2. Barriers to enrollment in post market studies 3. Common definitions for access related complications 4. Backwards compatibility of new products 5. Patient and HCP education on innovative products Vanessa Evans, Manisha Dadhania, Brigitte Schiller, MD

Polypharmacy is increasingly common, especially among older adults with multiple chronic conditions. While necessary, it can lead to drug interactions and other challenges. Let's look into key insights from Digital Doctor for more details: 💠 Perception Split: 52% of doctors view polypharmacy as defensive medicine, while 48% see it as offensive. 💠 Main Driver: The aging population (62%) is a reason for polypharmacy. 💠 Specialty Variations: Diabetologists, internists, and cardiologists most often encounter polypharmacy, while dermatovenereologists, gastroenterologists, and GPs see it less frequently. Download full report: https://lnkd.in/ehUUY5R4 #Healthcare #Polypharmacy #AgingPopulation #PatientCare #DigitalDoctor #Survey

Our meta-analysis recently showed that patients with Fibromyalgia X healthy controls had significantly lower levels of IL-B and higher levels of IL-6, IL-8, TNF-a, IFN-y, CRP, and BDNF. However, these changes do not seem specific to FM. https://lnkd.in/ddhA7yqT

Understanding how #NewTreatments are used in routine clinical practice across the globe help all stakeholders to make #BetterDecisions. Doing so in the quickest way possible while maintaining soundness and quality of research is of essence. In this new article from the #FOUNTAIN platform we report on the earliest #RWE around the use of #finerenone among persons with #T2D and #CKD in #Japan. There are similarities and differences to the US experience, but it seems clear that #patients and #physicians are confidently adopting a multiple MoA strategy. Read the full article below. https://lnkd.in/dr3tBX7S

Our recent publication on #apabetalone in renal impairment is getting some attention in the scientific community! Check out the full paper below: #biotechnology #KidneyDisease #HighlyCitedPapers

This large-scale, randomized controlled trial provided robust evidence supporting the renal benefits of semaglutide (Perkovic et al., 2024). Read more 👉 https://lttr.ai/ATu50 #Wellness #AntiAging #SignificantRiskFactor #RandomizedControlledTrials #BloodPressureRegulation #HighBloodPressure #wellness

Excited to share a proud moment for Gennova Biopharmaceuticals, a subsidiary of Emcure Pharmaceuticals! Our publication in the Journal of the American Heart Association (JAHA) reinforces the efficacy and safety of Tenecteplase for acute ischemic stroke in real-world clinical settings. Our registry-based study of 1,015 patients across India demonstrates the groundbreaking benefits of 0.2 mg/kg Tenecteplase, showing significant neurological improvement within 4.5 hours of symptom onset. Importantly, our Tenecteplase has been registered in India long before global findings confirmed its potential, reflecting our leadership in innovative stroke care. This pivotal research also highlights the practical advantages of Tenecteplase, such as its ease of administration, making it a game-changer for healthcare providers and offering new hope for stroke patients worldwide. Discover more: https://lnkd.in/drMdBhWZ

Access the March issue of Kidney360! Discover the latest educational papers on cutting edge clinical research, review engaging editorials, explore global perspective pieces, and more. Read this month’s top picks: ➡ What Are the Impacts of Introducing an SGLT2 Inhibitor after a Recent Episode of Acute Kidney Injury?: https://bit.ly/3TUNns5 ➡ Mortality, Health Care Burden, and Treatment of CKD: A Multinational, Observational Study (OPTIMISE-CKD): https://bit.ly/43Fewm4 ➡ Peritoneal Dialysis (PD) Patient and Nurse Preferences around Novel and Standard Automated PD Device Features: https://bit.ly/3IUPPJ5 ➡ Patient-Level and Center-Level Factors Associated with Required Predonation Weight Loss among Obese Living Kidney Donors: https://bit.ly/4ajk34E ➡ Global Perspectives in AKI: Sri Lanka: https://bit.ly/3TT6Aus Learn from these articles and more: https://bit.ly/3Ued87h   Pro Tip: Take advantage of the Read Out Loud feature to listen to the latest research while on the go. Click the “listen” speaker in your article of choice to enjoy listening anywhere, anytime.

"Medication request approved!" a.k.a prior-authorization (PA), Malaysian version. 😅 . One of the most rewarding moments for an obesity medicine physician is securing health coverage approval for our patients. . Delighted to have obtained approval for a patient with severe obesity, DM, and CKD to receive semaglutide 1mg and dapagliflozin. . FLOW study: Semaglutide 1mg for CKD and DM. DAPA-CKD study: Dapagliflozin for CKD alone. Both are also shown to help in weight loss (secondary outcome).

Dehydration is a serious issue for older adults, often leading to increased disability, longer hospital stays, and even death. Early detection is crucial, but classic signs can be misleading or absent. While blood tests can assess dehydration, we urgently need less-invasive and timely methods for better care. Let's prioritize hydration and health for our seniors! #ElderCare #DehydrationAwareness #HealthTech https://awaresciences.com/